Journal Watch · British Journal of Pharmacology · 2026
Up-regulation of the kinase LRRK2, in enteric glia contributes to mucosal barrier impairment in Parkinson's disease via secretory autophagy.
In co-culture experiments, α-synuclein and lipopolysaccharide promoted enteric gliosis and LRRK2 up-regulation in glial cells, contributing to IEB impairment via secretory autophagy.<h4>Conclusions and implications</h4>These changes could influence bowel symptoms and central pathology associated with PD, via the gut-brain axis.
TL;DR
In co-culture experiments, α-synuclein and lipopolysaccharide promoted enteric gliosis and LRRK2 up-regulation in glial cells, contributing to IEB impairment via secretory autophagy.<h4>Conclusions and implications</h4>These changes could influence bowel symptoms and central pathology associated with PD, via the gut-brain axis.
Key findings
- Enteric gliosis was evaluated by detection of GFAP<sup>+</sup> cells co-expressing LRRK2; IEB was tested by mucins detection and quantification of Muc-2, tight junction proteins and secretory autophagy.
- In vitro co-cultures between EGCs and IECs were performed to investigate glial LRRK2-mediated gut barrier alterations.<h4>Key results</h4>A53T mice, without central neuroinflammation, showed intestinal disturbances, colonic α-synuclein accumulation and an increase in colonic GFAP<sup>+</sup>/LRRK2<sup>+</sup> glial cells before brain pathology.
- Moreover, PD animals displayed IEB alterations and increased colonic autophagosomes, suggesting a shift towards secretory autophagy.
- In co-culture experiments, α-synuclein and lipopolysaccharide promoted enteric gliosis and LRRK2 up-regulation in glial cells, contributing to IEB impairment via secretory autophagy.<h4>Conclusions and implications</h4>These changes could influence bowel symptoms and central pathology associated with PD, via the gut-brain axis.
What they did
Therefore, we investigated the role of LRRK2 in IEB changes associated with PD, focusing on its role in the interplay between enteric glial cells (EGCs) and intestinal epithelial cells (IECs).<h4>Experimental approach</h4>Human A53T α-synuclein transgenic (Tg) mice (9 months old) were provided a model of early PD. Central neuroinflammation was studied by IBA-1 staining. Intestinal motility, colonic α-synuclein and LRRK2 expression were assessed.
Full abstract (original)
Background: <h4>Background and purpose</h4>Patients with Parkinson's disease (PD) show intestinal epithelial barrier (IEB) alterations, enteric gliosis and inflammation that could contribute to gastrointestinal symptoms. Moreover, changes in leucine rich-repeat kinase 2 (LRRK2) expression/activity have been associated with PD development and related intestinal inflammation. However, the molecular determinants linking LRRK2, enteric gliosis and IEB impairment remain unclear.
What they did: Therefore, we investigated the role of LRRK2 in IEB changes associated with PD, focusing on its role in the interplay between enteric glial cells (EGCs) and intestinal epithelial cells (IECs).<h4>Experimental approach</h4>Human A53T α-synuclein transgenic (Tg) mice (9 months old) were provided a model of early PD. Central neuroinflammation was studied by IBA-1 staining. Intestinal motility, colonic α-synuclein and LRRK2 expression were assessed.
Results & conclusions: Enteric gliosis was evaluated by detection of GFAP<sup>+</sup> cells co-expressing LRRK2; IEB was tested by mucins detection and quantification of Muc-2, tight junction proteins and secretory autophagy. In vitro co-cultures between EGCs and IECs were performed to investigate glial LRRK2-mediated gut barrier alterations.<h4>Key results</h4>A53T mice, without central neuroinflammation, showed intestinal disturbances, colonic α-synuclein accumulation and an increase in colonic GFAP<sup>+</sup>/LRRK2<sup>+</sup> glial cells before brain pathology. Moreover, PD animals displayed IEB alterations and increased colonic autophagosomes, suggesting a shift towards secretory autophagy. In co-culture experiments, α-synuclein and lipopolysaccharide promoted enteric gliosis and LRRK2 up-regulation in glial cells, contributing to IEB impairment via secretory autophagy.<h4>Conclusions and implications</h4>These changes could influence bowel symptoms and central pathology associated with PD, via the gut-brain axis.
Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70623 · PubMed 42593416.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking British Journal of Pharmacology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this British Journal of Pharmacology study find?
In co-culture experiments, α-synuclein and lipopolysaccharide promoted enteric gliosis and LRRK2 up-regulation in glial cells, contributing to IEB impairment via secretory autophagy.<h4>Conclusions and implications</h4>These changes could influence bowel symptoms and central pathology associated with PD, via the gut-brain axis.
What type of study is this?
It is a preclinical (animal / model) study, published in British Journal of Pharmacology in 2026. Therefore, we investigated the role of LRRK2 in IEB changes associated with PD, focusing on its role in the interplay between enteric glial cells (EGCs) and intestinal epithelial cells (IECs).<h4>Experimental approach</h4>Human A53T α-synuclein transgenic (Tg) mice (9 months old) were provided a model of early PD.
Where can I read the original paper?
The original is at the publisher via DOI 10.1111/bph.70623. PubMed ID: 42593416. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/up-regulation-of-the-kinase-lrrk2-in-enteric-glia-contributes-to-mucosal-h70623/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides